Humacyte (NASDAQ:HUMA) Upgraded to “Hold” at Wall Street Zen

Wall Street Zen upgraded shares of Humacyte (NASDAQ:HUMA) from a sell rating to a hold rating in a research note released on Friday morning.

Other analysts have also recently issued reports about the stock. D. Boral Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Humacyte in a research report on Monday, June 9th. HC Wainwright started coverage on shares of Humacyte in a research note on Wednesday, May 14th. They set a “buy” rating and a $4.00 price objective on the stock. Finally, Benchmark decreased their target price on shares of Humacyte from $17.00 to $14.00 and set a “buy” rating for the company in a research report on Wednesday, May 14th. Two equities research analysts have rated the stock with a hold rating, six have given a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $11.71.

Humacyte Trading Down 4.5%

Shares of Humacyte stock opened at $2.12 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 3.68 and a quick ratio of 3.28. Humacyte has a 1 year low of $1.15 and a 1 year high of $9.79. The company has a market capitalization of $328.85 million, a P/E ratio of -3.07 and a beta of 2.00. The business has a 50 day moving average price of $2.06 and a 200 day moving average price of $3.01.

Humacyte (NASDAQ:HUMA) last issued its quarterly earnings results on Tuesday, May 13th. The company reported ($0.10) earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.09. The business had revenue of $0.52 million during the quarter, compared to analyst estimates of $0.46 million. Sell-side analysts anticipate that Humacyte will post -1.27 EPS for the current fiscal year.

Insider Buying and Selling at Humacyte

In other news, Director Kathleen Sebelius purchased 50,000 shares of Humacyte stock in a transaction dated Tuesday, April 8th. The shares were bought at an average cost of $1.32 per share, with a total value of $66,000.00. Following the completion of the transaction, the director now directly owns 91,207 shares in the company, valued at $120,393.24. This trade represents a 121.34% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Dale A. Sander acquired 20,000 shares of the business’s stock in a transaction that occurred on Thursday, April 10th. The stock was bought at an average cost of $1.53 per share, for a total transaction of $30,600.00. Following the completion of the transaction, the chief financial officer now directly owns 40,600 shares in the company, valued at $62,118. This represents a 97.09% increase in their position. The disclosure for this purchase can be found here. Insiders have bought a total of 83,993 shares of company stock worth $118,224 over the last ninety days. Corporate insiders own 5.10% of the company’s stock.

Institutional Inflows and Outflows

Institutional investors have recently modified their holdings of the company. Columbia Advisory Partners LLC acquired a new position in Humacyte in the 1st quarter valued at about $27,000. Hamilton Lane Advisors LLC bought a new position in Humacyte in the 1st quarter valued at approximately $37,000. Letko Brosseau & Associates Inc. bought a new position in Humacyte in the 1st quarter valued at approximately $42,000. Petros Family Wealth LLC bought a new position in Humacyte in the 4th quarter valued at approximately $50,000. Finally, Syon Capital LLC acquired a new position in Humacyte in the 4th quarter valued at approximately $54,000. 44.71% of the stock is currently owned by institutional investors and hedge funds.

About Humacyte

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.